Search results
Prudential PLC Cuts Stock Position in Biogen Inc. (NASDAQ:BIIB)
ETF DAILY NEWS· 5 days agoPrudential PLC decreased its position in shares of Biogen Inc. (NASDAQ:BIIB – Free Report) by 52.4% during the 4th quarter, according to the company in ...
Research Analysts Set Expectations for Biogen Inc.’s FY2027 Earnings (NASDAQ:BIIB)
ETF DAILY NEWS· 4 days agoBiogen Inc. (NASDAQ:BIIB – Free Report) – Analysts at Wedbush lowered their FY2027 earnings estimates for Biogen in a research report ...
Biogen Inc. (NASDAQ:BIIB) Shares Sold by Crossmark Global Holdings Inc.
ETF DAILY NEWS· 7 days agoCrossmark Global Holdings Inc. decreased its position in shares of Biogen Inc. (NASDAQ:BIIB – Free Report) by 19.1% during the 4th quarter, HoldingsChannel ...
...Nasdaq: BIIB) Investors are Reminded of Upcoming July 2024 Legal Deadline and Encouraged to...
Benzinga· 7 days agoNEW YORK, June 08, 2024 (GLOBE NEWSWIRE) -- Leading law firm Bleichmar Fonti & Auld LLP announces the upcoming July 22, 2024, deadline in the Biogen Inc. (NASDAQ:BIIB) Securities Class Action Lawsuit. If you
Lost Money on Biogen Inc.(BIIB)? Join Class Action Suit Seeking Recovery - Contact The Gross Law...
Morningstar· 5 days agoNEW YORK, June 10, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Biogen Inc. (NASDAQ: BIIB). Shareholders who purchased ...
BIIB Investors Have Opportunity to Lead Biogen Inc. Securities Fraud Lawsuit
Morningstar· 4 days agoThe Law Offices of Frank R. Cruz announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against Biogen Inc. (" ...
BIIB Investors Have Opportunity to Lead Biogen Inc. Securities Fraud Lawsuit
Morningstar· 3 days agoLOS ANGELES, June 11, 2024 /PRNewswire/ -- , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Biogen Inc. ("Biogen ...
FDA Accepts Eisai's Filing of LEQEMBI® (lecanemab-irmb) Supplemental Biologics License Application...
Morningstar· 5 days agoTOKYO and CAMBRIDGE, Mass., June 9, 2024 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, ...
Eli Lilly inches higher premarket after FDA advisory panel backs Alzheimer's drug By Investing.com
Investing.com· 4 days agoShares in Eli Lilly (NYSE:LLY) edged higher in premarket U.S. trading on Tuesday after an advisory...
FDA Accepts Eisai's Filing of LEQEMBI® (lecanemab-irmb) Supplemental Biologics License Application...
Morning Times· 5 days agoEisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher ...